Scholarlink

Background <p>In July 2025, the S2k guideline on the diagnosis and treatment of interstitial cystitis/bladder pain syndrome (IC/BPS), developed under the auspices of the German Society of Urology (DGU), was published via the Association of the Scientific Medical Societies in Germany (AWMF) following comprehensive revision. The update aimed to improve diagnostic and therapeutic clarity and clinical applicability.</p> Objective <p>This article summarizes the key updates of the revised guideline and provides practical guidance for the clinical management of patients with IC/BPS.</p> Results <p>Major revisions include an updated definition and classification of IC/BPS in accordance with the WHO ICD-11 framework and an expanded overview of current pathogenetic concepts. A&#xa0;clearly structured, multimodal treatment algorithm has been implemented, integrating pharmacological, intravesical, interventional, neuromodulatory, and nonpharmacological therapies. Particular focus is placed on psychosocial comorbidities, individualized dietary management, pelvic floor physiotherapy, pain medicine, and urological rehabilitation.</p> Conclusion <p>The updated S2k guideline provides an evidence-informed, interdisciplinary, and clinically applicable framework for the management of IC/BPS. Careful diagnostic evaluation and individualized multimodal treatment strategies are essential to improve symptom control and long-term quality of life in affected patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aktualisierung der S2k-Leitlinie „Diagnostik und Therapie der interstitiellen Zystitis (IC/BPS)“

  • 期刊论文

  • 发表日期：

    2026年4月13日

查看全文
  • Pia V. Zimmermann,
  • Andreas Gonsior,
  • Winfried Vahlensieck,
  • Daniela Schultz-Lampel,
  • Andreas Wiedemann,
  • Björn T. Kaftan

摘要

Background

In July 2025, the S2k guideline on the diagnosis and treatment of interstitial cystitis/bladder pain syndrome (IC/BPS), developed under the auspices of the German Society of Urology (DGU), was published via the Association of the Scientific Medical Societies in Germany (AWMF) following comprehensive revision. The update aimed to improve diagnostic and therapeutic clarity and clinical applicability.

Objective

This article summarizes the key updates of the revised guideline and provides practical guidance for the clinical management of patients with IC/BPS.

Results

Major revisions include an updated definition and classification of IC/BPS in accordance with the WHO ICD-11 framework and an expanded overview of current pathogenetic concepts. A clearly structured, multimodal treatment algorithm has been implemented, integrating pharmacological, intravesical, interventional, neuromodulatory, and nonpharmacological therapies. Particular focus is placed on psychosocial comorbidities, individualized dietary management, pelvic floor physiotherapy, pain medicine, and urological rehabilitation.

Conclusion

The updated S2k guideline provides an evidence-informed, interdisciplinary, and clinically applicable framework for the management of IC/BPS. Careful diagnostic evaluation and individualized multimodal treatment strategies are essential to improve symptom control and long-term quality of life in affected patients.